大葉大學圖書館 |

Drug treatment of sleep disorders[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.8498061
書名/作者:	Drug treatment of sleep disorders/ edited by Antonio Guglietta.
其他作者:	Guglietta, Antonio.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	viii, 297 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Sleep disorders - Chemotherapy.
標題:	Biomedicine.
標題:	Pharmacology/Toxicology.
標題:	Neurosciences.
標題:	Pharmacotherapy.
標題:	Psychopharmacology.
ISBN:	9783319115146 (electronic bk.)
ISBN:	9783319115139 (paper)
內容註:	An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
摘要、提要註:	Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
電子資源:	http://dx.doi.org/10.1007/978-3-319-11514-6

Drug treatment of sleep disorders[electronic resource] /
Drug treatment of sleep disorders[electronic resource] /edited by Antonio Guglietta. - Cham :Springer International Publishing :2015. - viii, 297 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

ISBN: 9783319115146 (electronic bk.)

Standard No.: 10.1007/978-3-319-11514-6doiSubjects--Topical Terms:

603839
Sleep disorders
--Chemotherapy.

LC Class. No.: RC547

Dewey Class. No.: 616.8498061

Drug treatment of sleep disorders[electronic resource] /
LDR:02588nam a2200325 a 4500 001 425199
003 DE-He213
005 20150629165837.0
006 m d
007 cr nn 008maaau
008 151119s2015 gw s 0 eng d
020 $a 9783319115146 (electronic bk.)
020 $a 9783319115139 (paper)
024 7 $a 10.1007/978-3-319-11514-6 $2 doi
035 $a 978-3-319-11514-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC547
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.8498061 $2 23
090 $a RC547 $b .D794 2015
245 0 0 $a Drug treatment of sleep disorders $h [electronic resource] / $c edited by Antonio Guglietta.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a viii, 297 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
520 $a Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
650 0 $a Sleep disorders $x Chemotherapy. $3 603839
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Pharmacology/Toxicology. $3 463455
650 2 4 $a Neurosciences. $3 372208
650 2 4 $a Pharmacotherapy. $3 528865
650 2 4 $a Psychopharmacology. $3 372108
700 1 $a Guglietta, Antonio. $3 603838
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 463451
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-11514-6
950 $a Biomedical and Life Sciences (Springer-11642)